Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. - Wikidata - wikimedia - TriplyDB

Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.

Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.

http://www.wikidata.org/entity/Q39838078

about

Current status of immunotherapy The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study.Neoadjuvant sorafenib treatment of clear cell renal cell carcinoma and release of circulating tumor fragments.B-Raf regulation of integrin α4β1-mediated resistance to shear stress through changes in cell spreading and cytoskeletal association in T cells Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer.Immunological off-target effects of standard treatments in gastrointestinal cancers Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib.A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.Cancer immunotherapy--revisited.Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response?Immunocombination therapy for high-risk neuroblastoma.Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when.Modulation of immunity by antiangiogenic molecules in cancer.Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches.Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor.Chemotherapeutic targeting of cancer-induced immunosuppressive cells.Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.Immunological landscape and immunotherapy of hepatocellular carcinoma.Paradoxical exacerbation of chronic plaque psoriasis by sorafenib.Targeting regulatory T cells in tumors.Recent advances in immuno-oncology and its application to urological cancers.Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.The radiosensitizing effect of the aurora kinase inhibitors, ENMD-2076, on canine mast cell tumours in vitro.Interleukin 10-expressing B cells inhibit tumor-infiltrating T cell function and correlate with T cell Tim-3 expression in renal cell carcinoma.miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency.The role and significance of VEGFR2+ regulatory T cells in tumor immunity Influence of tumors on protective anti-tumor immunity and the effects of irradiation.Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.CAR-T cells and combination therapies: What's next in the immunotherapy revolution?Identifying the optimal anticancer targets from the landscape of a cancer-immunity interaction network.HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients.Nanomaterials for cancer immunotherapy.Treg cells as potential cellular targets for functionalized nanoparticles in cancer therapy.

P2860

Q26773314-791B15B3-7CDA-40D1-8264-9140C6FA80CD Q26783291-2056D7EF-4764-44B9-8D1E-A0B0648DEC60 Q27335748-68825FF2-3B7F-48EB-ADE4-B56CA11F3F3F Q28066486-F23E3FFE-A740-4652-86E6-793F3D79AB0B Q28393614-72198767-0AFD-4707-9635-7E4EDCE6DE46 Q33606102-8CB0DA90-B804-455F-828F-C8908B7F33B1 Q33891216-18D39151-157B-4CF7-ABA9-76A2927E0874 Q34044770-2A7880A2-9E29-4E1F-870F-B5866CA50C87 Q35801911-A5ECD7D6-033D-4EF1-810B-6AE9B379DB46 Q35802508-2687A503-9310-4464-A1B2-3BDD9D9C9DB4 Q36057441-DE9B5F30-F826-4DB1-A845-8EDA5240AF91 Q37404086-90BF4A3B-570A-41C7-BA7D-C7CF852B8D1C Q37522371-3D63BE29-DB2A-418D-A61E-C04E4B4994D5 Q37665918-2378EB67-0E08-437E-9536-178411017FF9 Q37908998-D3A81524-ACAD-4CC1-9BF5-352EEF7E8072 Q37987862-C77B71E6-E09E-40B4-A67F-87C5BB8BFE3F Q37991024-41CE5E67-7F3C-4954-A5C3-9F98C44D462D Q38020245-24C158C6-78B2-4D78-B3D2-65C60E7BFBEE Q38074154-68B6A5EC-5B90-41C9-90FA-211C05B6EB1A Q38099023-D0F2BE09-4464-4AE4-8B1E-DED2F2EAC8DD Q38151588-F9202112-D680-4A71-8046-431B79636910 Q38207980-AD4CFD7E-DE0D-4D77-BEE0-50A3A384C0D2 Q38349665-1BA5A658-A14C-43FB-B9BB-B2625161AAAB Q38611895-FF79D46E-70CA-4B03-99CB-42B8AFA6246F Q38669355-08D7334D-9302-455E-B3C1-F76596B0E6BD Q38703565-81485866-F0C9-4298-BFBD-B8FE3D579BDF Q38819745-D3CFE626-0D09-4DB4-87DD-26CBC9A85230 Q38870929-695BF320-08AE-4761-8504-8F3D6A453D01 Q39131172-7D82D64D-D239-4E43-9BFB-30AB1C7E4353 Q39140093-40E416DD-0761-4BD8-AE50-C4D6C6432D41 Q40160532-7D6FF0A1-B463-4FD0-837B-785F4911FB2D Q41049761-2657CCDF-48E2-4352-B4EF-0EBB807D73D8 Q41499942-89E53B29-15AF-4F69-A584-D7689D540C13 Q42945799-861F90CF-3558-404F-9B21-5155CB5B8782 Q45914110-B2E4DCC8-F9DA-46D5-AA68-8F7A225BED17 Q47285613-A1AD3761-6E26-4573-92B2-71332D08C73B Q47952036-72457D40-E3DB-4F5F-84CB-2E9F8F34D262 Q48335681-1B2C58A3-2E05-4016-B897-D6059292FB5E Q48646732-3850DA60-DB4C-419F-96DB-EBF7CBBA8851 Q51799863-E8D5B121-DB01-45DB-B4F5-6375890C9D32

P2860

Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.

http://www.wikidata.org/entity/Q39838078

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Sorafenib reduces the percenta ...... renal cell carcinoma patients.

@en

Sorafenib reduces the percenta ...... renal cell carcinoma patients.

@nl

type

label

Sorafenib reduces the percenta ...... renal cell carcinoma patients.

@en

Sorafenib reduces the percenta ...... renal cell carcinoma patients.

@nl

prefLabel

Sorafenib reduces the percenta ...... renal cell carcinoma patients.

@en

Sorafenib reduces the percenta ...... renal cell carcinoma patients.

@nl

P1433

Q39838078-6C5C4F7E-FDD1-46B5-841E-79B9DA8CC24E

P1476

Q39838078-6EBA971F-EFEA-497C-AFBC-19FDF428B254

P2093

Q39838078-33941755-DC65-4891-9B0F-22AF7E61E7F2

Q39838078-38477C81-0402-4D6E-BEC0-9F28DDCFF4FF

Q39838078-7A9A0573-29E0-49F9-9324-EC3399DD6ACE

Q39838078-7D5F21C6-71CF-4690-857C-584EFA5A789A

Q39838078-9B3875FC-39E9-4B67-AA58-3E8E72D40C38

Q39838078-D451C8DF-5A90-489C-BB84-59AD3646EDB4

P2860

Q39838078-01A89497-FFC5-40B3-AED2-B505000BD8C2

Q39838078-14F8C653-E77A-4E1B-BD0E-E13634480CAF

Q39838078-25EEC09C-1E1E-4AF3-B069-41BD91034F52

Q39838078-2B3D3BEA-24E8-4983-ABF7-8760E850385C

Q39838078-37A06FAE-BA7D-47FF-A432-63700C9F1284

Q39838078-3DA0DB1C-BFFB-4EEF-856B-0E7F2611AAF2

Q39838078-47362DE8-5EAD-467F-97AD-893892F6DBD7

Q39838078-4A7C85CF-DE3F-45FE-9AB6-F10753F69016

Q39838078-4B3659DB-2825-487F-828A-9272F4305C13

Q39838078-4D37CB41-004B-49A7-BCCB-173E69DD26A5

P304

Q39838078-8AA4A2B5-58C1-42F1-A96A-943AE44C8896

P31

Q39838078-B2047475-7A79-4642-BE72-E78A34067091

P356

Q39838078-90E081EB-7D3F-4AC3-A91E-2C812C836012

P433

Q39838078-64CE18D7-DC03-4F6E-9451-C58CE3B8E1CC

P478

Q39838078-7F5ABE3A-784B-4414-AE6E-9279C10CF214

P50

Q39838078-4F460C37-354D-41B6-9C78-2603809D16D0

Q39838078-795DA963-59C9-4CC6-AF95-9732D9AB79A0

Q39838078-F8AFAF0C-0685-4BC6-A4A2-05D40C0ED0DA

P577

Q39838078-44C38094-B030-44C7-A8B5-63BB5379FEE8

P698

Q39838078-8BD45BEB-67F7-4770-AD8C-33AB5083ACE5

P921

Q39838078-14545667-CFC2-44B8-BB6F-680B54F93C5D

P356

P1433

International Journal of Cancer

P1476

Sorafenib reduces the percenta ...... renal cell carcinoma patients

@en

P2093

Carla M L van Herpen

http://www.w3.org/2001/XMLSchema#string

Christina A Hulsbergen-vandeKaa

http://www.w3.org/2001/XMLSchema#string

Gosse J Adema

http://www.w3.org/2001/XMLSchema#string

Ingrid M E Desar

http://www.w3.org/2001/XMLSchema#string

Peter F A Mulders

http://www.w3.org/2001/XMLSchema#string

Winette T A van der Graaf

http://www.w3.org/2001/XMLSchema#string

P2860

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2

Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines.

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance.

All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation

Tregs and rethinking cancer immunotherapy.

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

Tuning microenvironments: induction of regulatory T cells by dendritic cells

Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein

P304

507-512

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.25674

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

129

http://www.w3.org/2001/XMLSchema#string

P50

Jolanda de Vries

Joannes F. M. Jacobs

P577

2010-11-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20839259

http://www.w3.org/2001/XMLSchema#string

P921